Eli Lilly (NYSE: LLY) has agreed to acquire US-based Ajax Therapeutics, a private New York-incorporated biopharmaceutical company, for up to USD 2.3 billion in cash. The transaction extends Lilly's oncology franchise into myeloproliferative neoplasms (MPNs), anchored by Ajax's lead asset AJ1-11095, a Type II JAK2 inhibitor currently in Phase I clinical development.
The total consideration of up to USD 2.3 billion is structured as an upfront cash payment plus subsequent payments contingent on the achievement of defined clinical and regulatory milestones. The precise split between the upfront component and milestone-linked payments has not been publicly disclosed. As a full corporate acquisition, Lilly acquires worldwide rights to all Ajax assets, including AJ1-11095, with no territorial carve-outs disclosed. A transaction closing date was not specified in available materials.
Type II JAK2 Inhibition
The mechanistic basis of the Lilly Ajax Therapeutics acquisition centers on AJ1-11095's binding mode. Current approved JAK inhibitors — including ruxolitinib and fedratinib — operate as Type I inhibitors, engaging JAK2 in its active, DFG-in conformation. AJ1-11095 binds the inactive DFG-out conformation of JAK2, a Type II binding mechanism that sterically occludes the allosteric pocket and is associated with higher kinase selectivity and more durable target engagement relative to Type I agents.
This distinction carries clinical relevance in myelofibrosis and polycythemia vera, where the JAK2 V617F driver mutation sustains constitutive kinase activation. Type I inhibitors achieve partial suppression but are constrained by on-target toxicity at doses required for deeper pathway inhibition. A Type II binding mode may permit more complete JAK2 inhibition at tolerated doses, though this hypothesis remains subject to clinical validation. First proof-of-concept data from the Phase I study of AJ1-11095 are expected to be presented later in 2026.